The optimal regimen of bevacizumab for recurrent XXXX : does dose matter?

@entity1 @entity2600 @entity5 @entity463 @entity1349
UNASSIGNED: The FDA-approved schedule and dose of bevacizumab (BVZ) for recurrent @entity463 (rGB) (10  mg/kg q 2  weeks) were adopted from systemic @entity5 protocols. No dose-defining studies have been performed for @entity463 . We began using BVZ for the treatment of rGB in 2005 at the dose of 5  mg/kg every 2  weeks combined with @entity2600 , and later as single agent. Our previous report of 20 @entity1 treated with BVZ 5  mg/kg every 2  weeks showed similar response rates and @entity1349 ( @entity1349 ) compared to other BVZ treatment protocols, with less adverse effects. In this study we retrospectively reviewed our 7 year experience with BVZ in 162 rGB @entity1 . Treatment outcomes were analyzed from 87 @entity1 who received BVZ at 5  mg/kg and 75 @entity1 at 10  mg/kg. While median age was similar in both groups, the median KPS was significantly higher in the group treated with 10  mg/kg BVZ (85 versus 60). There was no significant difference in @entity1349 or progression free survival (PFS) between the groups treated with BVZ 5 versus 10  mg/kg. Overall survival was significantly improved in the subgroup treated with cytotoxic therapy in addition to BVZ 10  mg/kg. There were more adverse events seen with BVZ 10  mg/kg. There is no significant difference in @entity1349 for rGB treated with BVZ 5  mg/kg versus 10  mg/kg when given as monotherapy. The smaller dose was slightly less toxic. Addition of cytotoxic therapy resulted in prolongation of @entity1349 in a small subgroup of BVZ 10  mg/kg.
